FDA grants approval of amivantamab-vmjw (Rybrevant) for treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations

Approval for this EGFR-targeting bispecific antibody is based on data which showed an overall response rate of 40% and a median duration of response of 11.1months in 81 patients whose disease had progressed on or after platinum-based chemotherapy.

Source:

FDA